← Leaderboards
Gerald B Pier
Brigham And Women'S Hospital
$23,267,480
Attributed
$23,686,302
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,686,302 · 9
By mechanism
R01$20,481,620 · 6
U54$2,300,062 · 1
R21$904,620 · 2
Top collaborators
- Xuefei Huang1 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Guo-Ping Shi$19,551,120
- Alison J. Quayle$3,973,361
Others in their field
Top investigators on “Virulence”
- Ronald B Corley · Boston University Medical Campus$43,000,000
- Joseph Heitman · Duke University$29,765,716
- Vanessa Sperandio · University Of Wisconsin-Madison$29,177,087
- Adolfo Garcia-Sastre · Jackson Laboratory$28,883,338
- John J Mekalanos · Harvard Medical School$28,747,360
- Scott J Hultgren · Washington University$28,322,020
Research focus
VirulencePseudomonas AeruginosaImmunityInfectionAntibodiesIn VitroSurfaceVaccinesLipopolysaccharidesLaboratory MouseEvaluationBaseStaphylococcus AureusPathogenPolysaccharidesBacteriaOligosaccharidesOrganismCystic FibrosisPoly-N-Acetyl GlucosamineMolecularImmune ResponseBacterial VaccinesPathology
Grant awards (62)
Deciphering the amine/acetylation code of PNAG through comprehensive libraries of synthetic oligosaccharides for effective anti-microbial vaccines$837,644
R01 · FY2025 · AI
Development of a model of Gonococcal conjunctivitis for vaccine evaluations$221,854
R21 · FY2024 · AI · contact PI
Development of a model of Gonococcal conjunctivitis for vaccine evaluations$264,708
R21 · FY2023 · AI · contact PI
Pathogenesis of microbial anterior eye diseases$425,276
R01 · FY2018 · EY · contact PI
Pathogenesis of microbial anterior eye diseases$425,276
R01 · FY2017 · EY · contact PI
Pathogenesis of microbial anterior eye diseases$382,748
R01 · FY2016 · EY · contact PI
Pathogenesis of microbial anterior eye diseases$416,677
R01 · FY2015 · EY · contact PI
Pathogenesis of microbial anterior eye diseases$424,052
R01 · FY2014 · EY · contact PI
Synthetics PNAG and multi-component vaccines against emerging pathogens$410,002
U54 · FY2013 · AI · contact PI
Pathogensis of Bacterial corneal infection$367,826
R01 · FY2013 · EY · contact PI
Synthetics PNAG and multi-component vaccines against emerging pathogens$468,318
U54 · FY2012 · AI · contact PI
Pathogensis of Bacterial corneal infection$387,186
R01 · FY2012 · EY · contact PI
Synthetics PNAG and multi-component vaccines against emerging pathogens$482,707
U54 · FY2011 · AI · contact PI
Pathogensis of Bacterial corneal infection$386,233
R01 · FY2011 · EY · contact PI
Synthetics PNAG and multi-component vaccines against emerging pathogens$505,031
U54 · FY2010 · AI · contact PI
Poly-N-acetyl glucosamine as a vaccine for bacterial pathogens$465,189
R01 · FY2010 · AI · contact PI
Pathogensis of Bacterial corneal infection$402,326
R01 · FY2010 · EY · contact PI
Poly-N-acetyl glucosamine as a vaccine for bacterial pathogens$458,355
R01 · FY2009 · AI · contact PI
Synthetics PNAG and multi-component vaccines against emerging pathogens$434,004
U54 · FY2009 · AI · contact PI
Pathogensis of Bacterial corneal infection$405,388
R01 · FY2009 · EY · contact PI
CFTR and infection of cystic fibrosis patients$388,400
R01 · FY2009 · HL · contact PI
Virulence and Immunity to Mucoid P. aeruginosa$380,786
R01 · FY2009 · AI · contact PI
Acquired Immunity and Vaccination for P. aeruginosa$341,698
R01 · FY2009 · AI · contact PI
Poly-N-acetyl glucosamine as a vaccine for bacterial pathogens$447,179
R01 · FY2008 · AI · contact PI
CFTR and infection of cystic fibrosis patients$388,400
R01 · FY2008 · HL · contact PI
Pathogenesis of P. aeruginosa corneal infection$387,085
R01 · FY2008 · EY · contact PI
Virulence and Immunity to Mucoid P. aeruginosa$380,786
R01 · FY2008 · AI · contact PI
Acquired Immunity and Vaccination for P. aeruginosa$341,698
R01 · FY2008 · AI · contact PI
Poly-N-acetyl glucosamine as a vaccine for bacterial pathogens$444,795
R01 · FY2007 · AI · contact PI
Pathogenesis of P. aeruginosa corneal infection$395,853
R01 · FY2007 · EY · contact PI
CFTR and infection of cystic fibrosis patients$388,400
R01 · FY2007 · HL · contact PI
Virulence and Immunity to Mucoid P. aeruginosa$388,161
R01 · FY2007 · AI · contact PI
Acquired Immunity and Vaccination for P. aeruginosa$348,315
R01 · FY2007 · AI · contact PI
Poly-N-acetyl glucosamine as a vaccine for bacterial pathogens$445,990
R01 · FY2006 · AI · contact PI
CFTR and infection of cystic fibrosis patients$400,000
R01 · FY2006 · HL · contact PI
Virulence and Immunity to Mucoid P. aeruginosa$399,755
R01 · FY2006 · AI · contact PI
Pathogenesis of P. aeruginosa corneal infection$398,931
R01 · FY2006 · EY · contact PI
Acquired Immunity and Vaccination for P. aeruginosa$358,718
R01 · FY2006 · AI · contact PI
Virulence and Immunity to Mucoid P. aeruginosa$407,782
R01 · FY2005 · AI
Pathogenesis of P. aeruginosa corneal infection$407,782
R01 · FY2005 · EY
Virulence and Immunity to Staphylcocci$372,056
R01 · FY2005 · AI
CFTR and Infection of Cystic Fibrosis patients$335,050
R01 · FY2005 · HL
Acquired Immunity and Vaccination for P aeruginosa$308,963
R01 · FY2005 · AI
Virulence and Immunity to Staphylcocci$372,549
R01 · FY2004 · AI
CFTR and Infection of Cystic Fibrosis patients$335,050
R01 · FY2004 · HL
ACQUIRED IMMUNITY AND VACCINATION FOR P AERUGINOSA$328,324
R01 · FY2004 · AI
VIRULENCE AND IMMUNITY TO MUCOID P. AERUGINOSA$409,003
R01 · FY2003 · AI
CFTR and Infection of Cystic Fibrosis patients$385,220
R01 · FY2003 · HL
Virulence and Immunity to Staphylcocci$373,021
R01 · FY2003 · AI
ACQUIRED IMMUNITY AND VACCINATION FOR P AERUGINOSA$367,025
R01 · FY2003 · AI
VIRULENCE AND IMMUNITY TO MUCOID P. AERUGINOSA$409,433
R01 · FY2002 · AI
CFTR and Infection of Cystic Fibrosis patients$376,675
R01 · FY2002 · HL
Virulence and Immunity to Staphylcocci$373,476
R01 · FY2002 · AI
ACQUIRED IMMUNITY AND VACCINATION FOR P AERUGINOSA$296,217
R01 · FY2002 · AI
CFTR and Infection of Cystic Fibrosis patients.$49,928
R01 · FY2002 · HL
ACQUIRED IMMUNITY AND VACCINATION FOR P AERUGINOSA$31,535
R01 · FY2002 · AI
VIRULENCE AND IMMUNITY TO MUCOID P. AERUGINOSA$399,425
R01 · FY2001 · AI
Virulence and Immunity to Staphylcocci$367,971
R01 · FY2001 · AI
ACQUIRED IMMUNITY AND VACCINATION FOR P AERUGINOSA$329,509
R01 · FY2001 · AI
VIRULENCE AND IMMUNITY TO STAPHYLOCOCCI$418,058
R21 · FY2000 · AI
ACQUIRED IMMUNITY AND VACCINATION FOR P AERUGINOSA$329,874
R01 · FY2000 · AI
CFTR AND INFECTION OF CYSTIC FIBROSIS PATIENTS$306,626
R01 · FY2000 · HL